Hard to Treat Diseases (HTDC) has announced that its China based subsidiary Mellow Hope, has finished the clinical trial of Cerebroprotein Hydrolysate for Injection (NUTRIPROTEIN) in India.
The company claims that the biological product is a unique nutriment for the brain. It helps CNS in multiple ways, regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation, protecting nerve cells against damages by ischemia and neurotoxins etc.
This clinical trial is a multicentre one, authorized by Mellow Hope and sponsored by our partner Lupin. The aim of this trial is to evaluate the efficacy and safety of this product in the management of subjects with Dementia in an open labeled, prospective, phase-III clinical trial. Through this clinical trial, this product has been approved with very good efficacy and safety, said the company.
Terry Yuan, CEO of HTDS, said: “With the completion of this clinical trial, we are expected to receive the registration approval for NUTRIPROTEIN within three months in India. As soon as we get the approval, we will launch this product in the local market. Without any competitors in India, we will win a large market shares.”